May 13 |
Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP)
|
May 10 |
Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) large institutional owners must be happy as stock continues to impress, up 3.2% over the past week
|
May 10 |
Q1 2024 Intellia Therapeutics Inc Earnings Call
|
May 9 |
Regeneron’s gene therapy triumphs twice, restoring hearing in children
|
May 8 |
Regeneron gene therapy improves hearing in child deafness
|
May 8 |
Regeneron gene therapy improves hearing in two children
|
May 8 |
Latest DB-OTO Results Show Dramatically Improved Hearing to Normal Levels in a Child with Profound Genetic Deafness within 24 Weeks and Initial Hearing Improvements in a Second Child at 6 Weeks
|
May 6 |
Regeneron Announces Investor Conference Presentations
|
May 6 |
Regeneron: Dissecting The First Quarter Results And Regulatory Setbacks
|
May 5 |
Wall Street Breakfast: The Week Ahead
|